Dyne Therapeutics Q4 2023 Earnings Report $14.01 +0.02 (+0.14%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Dyne Therapeutics EPS ResultsActual EPS-$1.09Consensus EPS -$0.92Beat/MissMissed by -$0.17One Year Ago EPSN/ADyne Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADyne Therapeutics Announcement DetailsQuarterQ4 2023Date3/5/2024TimeQ4 2023 Earnings ReleaseConference Call ResourcesPress ReleaseDYN Earnings HistoryPowered by Dyne Therapeutics Earnings HeadlinesDyne Therapeutics, Inc. (NASDAQ:DYN) Receives $49.91 Average PT from BrokeragesFebruary 21 at 1:33 AM | americanbankingnews.comDyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific ConferenceFebruary 14, 2025 | globenewswire.comWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary investor who picked Nvidia before shares exploded as high as 3,423%... Before April 30th, President Trump could make a shocking AI announcement...February 22, 2025 | InvestorPlace (Ad)Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In NowFebruary 6, 2025 | insidermonkey.comZacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and CardiolFebruary 3, 2025 | finance.yahoo.comDyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comSee More Dyne Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email. Email Address About Dyne TherapeuticsDyne Therapeutics (NASDAQ:DYN), a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.View Dyne Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
